drugset / Trial / NCT07011043
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Non-randomizedSequentialOpen-labelTreatment
Summary
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Timeline
- Start
- 2025-07-10
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budoprutug | Monoclonal antibody | — | Intravenous |